Literature DB >> 746357

Lecithin:cholesterol acyltransferase activation and lipid binding by synthetic fragments of apolipoprotein C-I.

A K Soutar, G F Sigler, L C Smith, A M Gotto, J T Sparrow.   

Abstract

Peptide fragments of apolipoprotein C-I (apoLP-C-I) have been synthesized by solid phase methodology. After purification, each peptide showed the correct amino acid analysis and was a single band by polyacrylamide gel electrophoresis. In density gradient ultracentrifugation with vesicles of dimyristoyl phosphatidylcholine, peptide fragments 32-57, 24-57, and 17-57 formed stable complexes while 39-57 did not. With mixed vesicles of dimyristoyl phosphatidylcholine-cholesterol 20 micrometer of the fragments 32-57, 24-57 and 17-57 stimulated lecithin:cholesterol acyltransferase (LCAT) activity 50, 60, and 100%, respectively, of the value found for apolipoprotein C-I, while fragment 39-57 was inactive. The results indicate that residues 17-57 contain the structural requirements for LCAT activation by apoLP-C-I, and that residues 32-57 represent one of the major phospholipid-binding regions of apoLP-C-I.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 746357

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest Suppl        ISSN: 0085-591X


  3 in total

1.  Aromatic residues in the C-terminal helix of human apoC-I mediate phospholipid interactions and particle morphology.

Authors:  Patrick F James; Con Dogovski; Renwick C J Dobson; Michael F Bailey; Kenneth N Goldie; John A Karas; Denis B Scanlon; Richard A J O'Hair; Matthew A Perugini
Journal:  J Lipid Res       Date:  2008-11-04       Impact factor: 5.922

2.  Identifying blood biomarkers and physiological processes that distinguish humans with superior performance under psychological stress.

Authors:  Amanda M Cooksey; Nausheen Momen; Russell Stocker; Shane C Burgess
Journal:  PLoS One       Date:  2009-12-18       Impact factor: 3.240

Review 3.  Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond.

Authors:  Elena V Fuior; Anca V Gafencu
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.